Table 4 Association between the clinicopathological variables and EGFR/HER2 protein expression or gene amplification (N = 220)
EGFR IHC staining intensity, N (%) | EGFR in situ hybridisation status, N (%) | HER2 IHC staining intensity, N (%) | HER2 in situ hybridisation status, N (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
0/1+ | 2+/3+ | P valuea | EGFR gene amplification | No EGFR gene amplification | P valuea | 0/1+ | 2+/3+ | P valuea | HER2 gene amplification | No HER2 gene amplification | P valuea | |
Patient gender | ||||||||||||
Female | 59 (39.9) | 20 (27.8) | NS | 8 (25.8) | 71 (37.6) | NS | 69 (36.5) | 10 (32.3) | NS | 8 (27.6) | 71 (37.2) | NS |
Male | 89 (60.1) | 52 (72.2) | 23 (74.2) | 118 (62.4) | 120 (63.5) | 21 (67.7) | 21 (72.4) | 120 (62.8) | ||||
Site of primary tumour | ||||||||||||
Distal oesophagus/GOJ/cardia | 49 (33.1) | 34 (47.2) | NS | 18 (58.1) | 65 (34.4) | 0.016 | 69 (36.5) | 14 (45.2) | NS | 14 (48.3) | 69 (36.1) | NS |
Corpus/antrum/pylorus | 99 (66.9) | 38 (52.8) | 13 (41.9) | 124 (65.6) | 120 (63.5) | 17 (54.8) | 15 (51.7) | 122 (63.9) | ||||
Histological differentiation grade | ||||||||||||
Grade I | 23 (15.5) | 7 (9.7) | NS | 2 (6.5) | 28 (14.8) | NS | 28 (14.8) | 2 (6.5) | NS | 2 (6.9) | 28 (14.7) | NS |
Grade II | 71 (48.0) | 32 (44.4) | 17 (54.8) | 86 (45.5) | 83 (43.9) | 20 (64.5) | 18 (62.1) | 85 (44.5) | ||||
Grade III | 54 (36.5) | 33 (45.8) | 12 (38.7) | 75 (39.7) | 78 (41.3) | 9 (29.0) | 9 (31.0) | 78 (40.8) | ||||
Postoperative Tb | ||||||||||||
pT1–pT2 | 54 (37.0) | 15 (21.4) | 0.029 | 4 (13.31) | 65 (34.9) | 0.020 | 63 (34.1) | 6 (19.4) | NS | 6 (20.7) | 63 (33.7) | NS |
pT3–pT4 | 92 (63.0) | 55 (78.6) | 26 (86.7) | 121 (65.1) | 122 (65.9) | 25 (80.6) | 23 (79.3) | 124 (66.3) | ||||
Postoperative stage | ||||||||||||
I–II | 100 (67.6) | 42 (58.3) | NS | 14 (45.2) | 128 (67.7) | 0.024 | 125 (66.1) | 17 (54.8) | NS | 15 (51.7) | 127 (66.5) | NS |
III–IV | 48 (32.4) | 30 (41.7) | 17 (54.8) | 61 (32.3) | 64 (33.9) | 14 (45.2) | 14 (48.3) | 64 (33.5) | ||||